OCC Insider Trading (Orthocell)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$208,495.77
Orthocell Share Price & Price History
Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET
Protect Your Trading Account With Options!
From Tradewins | Ad
This might be the opposite of what you’ve heard, but the real risk in the market now lies with stock trading… “Options Trading Made Easy” by expert Chuck Hughes will show you how the nature of options trading gives you the chance to profit no matter which way the market trends!
Get the e-book today!
>>>
Orthocell Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 9/23/2021 | Paul Anderson | Insider | Sell | 435,273 | A$0.48 | A$208,495.77 | | |
| 4/6/2021 | Lars Lidgren | Insider | Buy | 9,000 | A$0.54 | A$4,860.00 | | |
| 7/11/2019 | Matthew (Matt) Callahan | Insider | Issued | 21,053 | A$0.48 | A$10,000.18 | | |
A One Stop Shop for Everything Futures Trading
From RJO Futures | Ad
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.
SEC Filings (Institutional Ownership Changes) for Orthocell (ASX:OCC)
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia and internationally. The company's principal products include CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of tendons, peripheral nerves, bones, and articular cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation for the treatment of symptomatic defects of the articulating cartilage of the joints, primarily in the knee and ankle. In addition, the company develops Striate+ for use in bone and soft tissue repair; SMRT Graft for use in to augment repair of rotator cuff tendinopathy and tear; and Remplir, a nerve wrap. Orthocell Limited was incorporated in 2006 and is based in Murdoch, Australia.
Read More on Orthocell
Today's Range
Now: N/A
50 Day Range
MA: N/A
52 Week Range
Now: N/A
Volume
669,530 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Orthocell?
